Combined oral therapy with sildenafil and doxazosin for the treament of non-organic erectile dysfunction refractory to sildenafil monotherapy

A. F. De Rose, M. Giglio, P. Traverso, P. Lantieri, G. Carmignani

Research output: Contribution to journalArticlepeer-review

Abstract

The purpose of this work was to investigate the efficacy and safety of sildenafil in combination with doxazosin for the treatment of non-organic erectile dysfunction in patients who did not respond to sildenafil. We enrolled 28 patients with non-organic erectile dysfunction, for whom 3 months of sildenafil monotherapy had failed. They were divided in two random and homogeneous groups: 14 were treated with doxazosin (4 mg daily) and sildenafil (100mg 1 h before sexual intercourse); the other 14 patients received sildenafil and placebo. The results were assessed by means of the IIEF questionnaire before the beginning of the study, after 30 days of therapy and after 60 days. Of the 14 patients treated with doxazosin and sildenafil, 11 (78.6%) showed a statistically significant increase of IIEF; in the placebo group, only one patient (7.1%) recorded a significant IIEF increase. The differences observed in the two groups were statistically very significant (P=0.0016). Blood pressure did not show significant alterations. Side effects were minimal and even present during sildenafil monotherapy. The combination therapy with sildenafil and doxazosin resulted in the safe and effective treatment of men with non-organic erectile dysfunction for whom sildenafil alone had failed.

Original languageEnglish
Pages (from-to)50-53
Number of pages4
JournalInternational Journal of Impotence Research
Volume14
Issue number1
DOIs
Publication statusPublished - 2002

Keywords

  • Administration, oral
  • Doxazosin
  • Drug therapy, combination
  • Erectile dysfunction
  • Sildenafil

ASJC Scopus subject areas

  • Urology

Fingerprint Dive into the research topics of 'Combined oral therapy with sildenafil and doxazosin for the treament of non-organic erectile dysfunction refractory to sildenafil monotherapy'. Together they form a unique fingerprint.

Cite this